Cita APA

Derman, B. A., Stefka, A. T., Jiang, K., McIver, A., Kubicki, T., Jasielec, J. K., & Jakubowiak, A. J. (2021). Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J.

Chicago Style Citation

Derman, Benjamin A., Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, i Andrzej J. Jakubowiak. "Measurable Residual Disease Assessed By Mass Spectrometry in Peripheral Blood in Multiple Myeloma in a Phase II Trial of Carfilzomib, Lenalidomide, Dexamethasone and Autologous Stem Cell Transplantation." Blood Cancer J 2021.

Cita MLA

Derman, Benjamin A., et al. "Measurable Residual Disease Assessed By Mass Spectrometry in Peripheral Blood in Multiple Myeloma in a Phase II Trial of Carfilzomib, Lenalidomide, Dexamethasone and Autologous Stem Cell Transplantation." Blood Cancer J 2021.